Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine
Manufacturing is underway and doses of Moderna's Spikevax 2024-2025 formula will be ready to ship as early as August, pending...
COVID-19
Klick Health Adds 18 Senior Leaders as 27-Year Double-Digit Growth Spurt Continues
Independent health agency continues to attract industry’s brightest minds; fortifies teams companywide as part of commitment to delivering industry-leading innovation,...
Combined General Meeting of June 24, 2024
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / June 7, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the...
Ada Health, The Most Accurate AI for Care Navigation, Expands Its Leadership Team for Strategic Growth with Product and Business Development Hires
The AI-powered symptom assessment and care navigation platform, which gives 50M+ users access to its enterprise solutions, reaches key growth...
Moderna’s Investigational Therapeutic for Methylmalonic Acidemia (mRNA-3705) Selected by U.S. Food & Drug Administration for START Pilot Program
Center for Biologics Evaluation and Research has chosen mRNA-3705 as one of four investigational medicines for accelerated development to address...
Zomedica Announces Presentation of Compelling TRUFORMA(R) Research Findings and Educational Programs at Major Veterinary Internal Medicine Conference
New research data confirms superiority of TRUFORMA's Bulk Acoustic Wave Sensor technology in diagnosing feline hyperthyroidism ANN ARBOR, MI /...
Telehealth System Featuring Rokid Glass 2 Wins HHS Award
HANGZHOU, China, June 5, 2024 /PRNewswire/ -- Rokid's augmented reality (AR) devices are making significant inroads into the medical sector. Utilizing...
Masimo Joins Forces with the Mobilize Recovery 2024 Bus Tour
Collaborative Partnership Designed to Enhance Nationwide Efforts to Combat the Opioid Epidemic and Improve Addiction RecoveryIRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI),...
First Participants Vaccinated in IMUNON’s IMNN-101 Phase 1 Clinical Trial
DNA vaccine proof-of-concept study expected to demonstrate an “mRNA better” platform LAWRENCEVILLE, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- IMUNON,...
Intuitive Announces FDA Clearance of Revised da Vinci Xi and X Labeling on Radical Prostatectomy
FDA review of historic data shows patients who received robotic prostatectomies have overall cancer survival rates on par with open...
Theralase(R) Technology Effective in Virus Inactivation
TORONTO, ON / ACCESSWIRE / June 4, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage...
The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect
A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More SHELTON, CT...
Zomedica Increases Manufacturing Capacity with Expansion of its Roswell, Georgia Facility; Can Support Production to Five times Current Levels
Timely expansion enhances capacity amidst rapid sales growth ANN ARBOR, MI / ACCESSWIRE / June 4, 2024 / Zomedica Corp....
iCAD to Participate in the MedInvest MedTech, AI & Digital Health Conference
NASHUA, N.H., June 04, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create...
Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
HOUSTON, June 04, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ:BPTH) (“Bio-Path” or the “Company”), a biotechnology company leveraging its...
BioVie Announces Formation of Advisory Board for Bezisterim in Long COVID
Scientific Advisory Board to play pivotal role in guiding and accelerating bezisterim long COVID Phase 2b trial supported by an...
Hemostemix Announces Strategic Manufacturing Partnership with CytoImmune Therapeutics and $1,800,000 in Financing Commitments
Calgary, Alberta--(Newsfile Corp. - June 3, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) is pleased to...
Aptevo Participating in the BIO International Convention
SEATTLE, WA / ACCESSWIRE / June 3, 2024 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing...
Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival & Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection
At a median planned follow-up of the Phase 2b study at 34.9 months, mRNA-4157 (V940) in combination with KEYTRUDA reduced...
Microbot Medical Has Received FDA Approval to Proceed with its Pivotal Human Clinical Trial
The trial will be conducted in the U.S. and its results will complement the preclinical data on the LIBERTY® Endovascular...